Tesamorelin Guide: Reported Dosage, Reconstitution & Stacks

Tesamorelin at a glance

What it is

Tesamorelin (Egrifta) — a stabilized synthetic analog of growth-hormone-releasing hormone (GHRH 1-44).

Approved / researched for

FDA-approved to reduce excess visceral abdominal fat in HIV-associated lipodystrophy; studied off-label for visceral-fat and metabolic contexts.

Reported range

Label 1.28–2 mg/day across Egrifta formulations; off-label reports ~1–2 mg/day (examples, not recommendations).

Route reported

Subcutaneous injection into the abdomen.

Reported frequency

Once daily (short half-life; one daily GH pulse).

Reported cycle

Long-term — visceral fat re-accumulates within weeks of stopping.

Plasma half-life

8 min (Egrifta SV) / 11 min (Egrifta WR) per label; ~26–38 min reported for the original formulation.

Regulatory status

FDA-approved for HIV-lipodystrophy only; all other use off-label; WADA-prohibited.

Reported ranges from research/community — examples, not recommendations.

What it is / mechanism

Tesamorelin is a stabilized analog of the first 44 amino acids of human growth-hormone-releasing hormone (GHRH), modified at the N-terminus (a trans-3-hexenoyl group) to resist DPP-4 breakdown. It acts as a GHRH-receptor agonist on the pituitary, prompting the body's own pulsatile release of growth hormone, which in turn raises IGF-1 and promotes lipolysis of visceral (rather than subcutaneous) fat. Because it stimulates endogenous GH instead of supplying GH directly, it preserves a more physiologic release pattern — and its studied niche is specifically visceral adipose tissue.

Researched effects

In the pivotal Phase 3 program (roughly 800 people with HIV-associated lipodystrophy), tesamorelin reduced visceral adipose tissue by about 15–18% versus placebo over 26 weeks, lowered fasting triglycerides, and raised IGF-1; the reduction was largely maintained through 52 weeks. Reported effects reverse — visceral fat re-accumulates within weeks to months of stopping — so it is studied as long-term therapy rather than a short course. Non-HIV metabolic and liver-fat (NAFLD) uses have been explored in research but are not approved. These are research findings, not guaranteed outcomes.

Dosage — reported ranges (overview)

For the approved indication, the label dose is once-daily subcutaneous Egrifta 2 mg / Egrifta SV 1.4 mg / Egrifta WR 1.28 mg. Off-label community reports commonly describe roughly 1–2 mg subcutaneously once daily (sometimes at bedtime, occasionally on a 5-days-on/2-off pattern) — these are examples of what is reported outside the approved use, not a recommendation, and are not FDA-sanctioned. Because IGF-1 rises substantially, the label requires IGF-1 monitoring.

A printable protocol sheet with a reconstitution reference and an injection log comes with All-Access Lifetime.

Reconstitution — bac-water math

Pharmacy Egrifta products are mixed per their package insert. Research-grade lyophilized tesamorelin is reconstituted with bacteriostatic water. To read a dose in syringe units on a U-100 insulin syringe (100 units = 1 mL): volume in mL = dose ÷ concentration, then × 100 to convert to units. Worked example for a 10 mg research vial — the concentration column shows mcg/mL and the two dose columns show 1 mg and 2 mg examples in syringe units:

This is concentration math, not a dose recommendation.

Injection / administration basics

Reported administration is subcutaneous into the abdomen, once daily, using a U-100 insulin syringe; rotating the site within the region is commonly described because injection-site reactions and local fat changes are reported. For pharmacy products, follow the package-insert mixing and administration steps exactly. General handling concepts — sterile technique, site rotation, timing — are covered here as general information; the detailed workflow comes with All-Access Lifetime, which includes the printable protocol sheet and injection log for every compound. This is general educational information, not a personal administration protocol.

Half-life & frequency rationale

Tesamorelin clears fast, and the exact figure depends on which formulation is being described — a distinction most summaries flatten. The current FDA labels report a mean elimination half-life of 8 minutes for Egrifta SV (after a 1.4 mg subcutaneous dose) and 11 minutes for Egrifta WR (1.28 mg), both in healthy subjects; longer figures of roughly 26–38 minutes circulate for the original Egrifta formulation. Either way, once-daily dosing is sufficient because the downstream growth-hormone and IGF-1 response outlasts the peptide itself — the effect on body composition builds over weeks even though the molecule clears within the hour.

Stacking — overview

Because tesamorelin is itself a GHRH-receptor agonist, it is complementary with a GHRP (growth-hormone-releasing peptide) such as ipamorelin, but redundant with other GHRH analogs. Each combination is covered in depth — the mechanism-level rationale, what is reported in practice, and combination-specific cautions — in the paid Tesamorelin Stacking Module included with this guide.

For how combinations are grouped by research context, the named blends, and why a pre-mixed blend vial cannot be calculated from its total milligrams, see the peptide stacks guide.

Storage & handling

• Pharmacy Egrifta/SV/WR: store per the package insert (formulations differ; some historically refrigerated).
• Research lyophilized (unmixed): store cold and dark; long-term typically frozen.
• Reconstituted: refrigerate (~2–8°C); use within days to about two weeks; protect from light; swirl gently and do not shake or freeze.

Evidence File

Tesamorelin Evidence File: One Registry Record, Two Pivotal Trials, and a Mock Study

Tesamorelin has one of the deepest registry footprints of any peptide sold for research use: two pivotal Phase 3 trials, a 52-week extension that posts an outcome table, a dozen investigator-initiated randomized studies, and a set of terminated and withdrawn records almost nobody reads. This file works through the registered studies by NCT number, states which post results and which do not, traces the most-quoted tesamorelin figures back to the specific analysis each came from, and separates what the registry supports from what circulates as protocol. Every absence is stated with the searches and the registry fields behind it.

• A recruiting Phase 2 liver-fat trial in the registry is titled a mock study
• The 15-18 percent visceral fat figure mixes 26-week and 52-week results
• Both registered tesamorelin sleep studies were withdrawn with zero enrolled
• The 10-year malignancy cohort was terminated and posts no outcome data

Sourcing File

Tesamorelin Sourcing File: Three Correct Masses, a 96 Dalton Test, and a Label That Disagrees With Itself

Tesamorelin is a 44-residue peptide carrying two modifications that a routine certificate of analysis will not mention and a mass check will not always catch. This file assembles the identity record from PubChem, the FDA substance registry and both current prescribing information documents, shows the salt and charge-state arithmetic in full rather than asserting it, works through a certificate line by line, and sets out the substitution modes that a single mass measurement can and cannot resolve. It also documents where the published record runs out, and marks those points as unverified rather than filling them in.

• Tesamorelin acetate is about 92 percent peptide, so 10 mg gross is 9.24 mg
• Two FDA labels state one acetate ratio and imply two different acetate contents
• A vial reading 3358 or 3647 Da is sermorelin or CJC-1295, not tesamorelin
• Egrifta SV is reconstituted with sterile water, not bacteriostatic water

Benefit & Outcome Review

Tesamorelin Benefit and Outcome Review: What Held Up, What Was Over-Extended, What the Label Denies

Tesamorelin is unusual among research peptides in having approval-grade evidence for one specific claim and much weaker evidence for everything the market attaches to it. This review takes the claims one at a time, states what was measured, in whom, against what comparator and for how long, and grades each on that basis rather than on how often it is repeated. It separates imaging endpoints from histology, within-group changes from between-group differences, and target engagement from clinical effect, and it works through the safety table the compound's own prescribing information publishes.

• The label states it is not indicated for weight loss and is weight neutral
• Arthralgia was 13 percent on drug and 11 percent on placebo in the label table
• Anti-tesamorelin antibodies appeared in about half of patients by 26 weeks
• No human trial of tesamorelin combined with any GHRP has been registered

Guide FAQ

Quick answers about guide scope, access, and educational use context.